Nabsys closes expanded $38M equity round
Additional investment triggered by throughput-related milestonePROVIDENCE, R.I. , Nov. 9, 2022 /PRNewswire/ -- Nabsys, the pioneer in electronic w...
Source: businessinsider.com
Diagnostic Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Diagnostic Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Diagnostic Division Today - Breaking & Trending Today
Grifols (NASDAQ:GRFS) Downgraded to "Sell" at Zacks Investment Research
Grifols (NASDAQ:GRFS – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]
Source: etfdailynews.com
Zacks Investment Research Upgrades Grifols (NASDAQ:GRFS) to "Hold"
Grifols (NASDAQ:GRFS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous […]
Source: etfdailynews.com
Grifols (NASDAQ:GRFS) Upgraded to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a sell rating to a hold rating in a report issued on Friday morning, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic […]
Source: etfdailynews.com
Zacks Investment Research Upgrades Grifols (NASDAQ:GRFS) to Hold
Grifols (NASDAQ:GRFS – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, […]
Source: etfdailynews.com